Stockreport

Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial

Amylyx Pharmaceuticals, Inc.  (AMLX) 
PDF - AMX0114 was generally well-tolerated, with no treatment-related serious adverse events- Amylyx will proceed with opening enrollment of second cohort- Data are being pr [Read more]